What are the most common tirzepatide side effects?

Gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, and abdominal discomfort are among the most frequently reported, especially during dose escalation. Many are mild to moderate, but you should report severe or persistent symptoms to a clinician.

Updated September 2026 · Safety-first (YMYL)

Tirzepatide side effects and who should discuss risks first

Q: What is the boxed warning about?

FDA-approved tirzepatide labels include a boxed warning regarding thyroid C-cell tumors observed in rodents. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. People with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should discuss contraindications with a clinician and review the official label.

Q: Who should avoid tirzepatide?

Contraindications and precautions are listed on the official prescribing information and may include relevant thyroid cancer history/MEN2, hypersensitivity to the product, and other clinical situations. Pregnancy planning, history of pancreatitis, severe gastrointestinal disease, and other conditions require individualized clinician review. This page is not a complete list.

Understanding harms is as important as understanding average weight outcomes in trials. This page is an educational overview aligned with common label themes for FDA-approved tirzepatide products (Zepbound® / Mounjaro®). It is incomplete compared with the official prescribing information—always read the label and talk with a licensed clinician.

Emergency care: Seek urgent medical help for symptoms of a severe allergic reaction, severe abdominal pain (possible pancreatitis), or other emergency warning signs your clinician has described. This website cannot triage emergencies.

Common side effects

In clinical programs, gastrointestinal effects are among the most frequently reported, particularly while doses are being increased:

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain or discomfort
Decreased appetite
Injection-site reactions (for injectable products)

Many GI effects are mild to moderate and may lessen over time, but persistent or severe symptoms warrant clinical contact. Dehydration from vomiting/diarrhea can matter—especially for people with kidney disease.

Serious risks discussed on labels

Official labeling for FDA-approved tirzepatide products discusses serious risks that clinicians weigh against potential benefits. Themes include (non-exhaustive):

Boxed warning — thyroid C-cell tumors (rodents): Tirzepatide caused thyroid C-cell tumors in rats. It is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Contraindications related to personal/family history of MTC or MEN2 are described on the label.
Pancreatitis: Acute pancreatitis has been reported with incretin therapies; severe abdominal pain needs prompt evaluation.
Gallbladder problems: Rapid weight loss and GLP-1–class agents have been associated with biliary events in some contexts.
Hypoglycemia: Risk rises when combined with insulin or insulin secretagogues—dose adjustments may be needed under clinician care.
Acute kidney injury: Can follow severe GI fluid loss in susceptible patients.
Diabetic retinopathy complications: Relevant especially in people with type 2 diabetes and preexisting retinopathy—monitoring may be needed.
Hypersensitivity / anaphylaxis: Stop and seek care if a serious allergic reaction occurs.
Suicidal behavior and ideation: Monitor mood changes per clinician guidance and label recommendations for weight-management products.

This list is not a substitute for the Medication Guide or Full Prescribing Information.

Who should be especially cautious

Discuss tirzepatide thoroughly with a clinician before use if you have (examples—not exhaustive): history suggestive of MTC/MEN2, prior pancreatitis, severe gastrointestinal disease (e.g., severe gastroparesis), planned pregnancy or current pregnancy/breastfeeding questions, significant kidney disease, or complex diabetes regimens. Pediatric use and off-label situations require specialist judgment.

Compounded products and safety

Compounded tirzepatide is not FDA-approved. Quality, potency, sterility, and dosing clarity can differ from FDA-approved pens/vials. Adverse event reporting and product consistency may be harder to track. See compounded vs Zepbound®.

FAQ

What are the most common side effects?

GI effects—nausea, diarrhea, vomiting, constipation, abdominal discomfort—especially during dose escalation.

What is the boxed warning about?

Thyroid C-cell tumors in rodents; human relevance for MTC is unknown. People with relevant personal/family history should review contraindications with a clinician and the official label.

Who should avoid tirzepatide?

Follow label contraindications and clinician advice. This page is not a complete eligibility checklist.